Is complete response the answer?

scientific article

Is complete response the answer? is …
instance of (P31):
editorialQ871232
scholarly articleQ13442814

External links are
P356DOI10.1093/ANNONC/MDX215
P8608Fatcat IDrelease_6bfzma2kcvdufenlv74vc45asm
P698PubMed publication ID28633466

P50authorChristos M. HatzisQ57009658
P2093author name stringL Pusztai
B Szekely
P2860cites workRelationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer.Q41471514
European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?Q41523908
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.Q42921828
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.Q52907227
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.Q54534083
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.Q55071239
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-AnalysisQ35935516
Bevacizumab added to neoadjuvant chemotherapy for breast cancerQ36106083
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trialQ36219254
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancerQ37131869
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trialQ38443954
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer SubtypeQ39109484
Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer.Q40065597
Breast cancer statistics, 2015: Convergence of incidence rates between black and white womenQ40379855
P433issue8
P304page(s)1681-1683
P577publication date2017-08-01
P1433published inAnnals of OncologyQ326122
P1476titleIs complete response the answer?
P478volume28

Reverse relations

cites work (P2860)
Q64059986Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
Q64952029Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.

Search more.